New York, January 9, 2026, 13:01 EST — Regular session
Immunome, Inc. shares jumped on Friday, outpacing a firmer biotech tape. The Nasdaq-listed stock (IMNM) was up 7.4% at $21.97, after trading between $20.71 and $22.00.
The move keeps attention on Immunome’s lead drug, varegacestat, being developed for desmoid tumors — non-cancerous growths in connective tissue that can still be painful and hard to treat. The company has said it plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration in the second quarter of 2026; an NDA is the formal request for approval to sell a drug.
Broader markets gave risk assets some help. U.S. stocks rose after a softer December jobs report kept bets for further Federal Reserve rate cuts alive, even as the unemployment rate dipped to 4.4%. The SPDR S&P Biotech ETF was up about 1.3% and the iShares Nasdaq Biotechnology ETF gained about 0.6%.
Immunome on Thursday disclosed stock-option “inducement” grants — awards used to recruit new hires that require a public notice under Nasdaq rules. The company said it granted options covering 93,000 shares to three new employees, with an exercise price of $20.82, and vesting over four years. Business Wire
The stock has been a battleground since Immunome reported in December that its Phase 3 study met its main goal, cutting the risk of disease progression or death by 84% versus placebo. Varegacestat is a gamma secretase inhibitor, a drug class that blocks a signaling pathway tied to tumor growth, and it sets up competition in desmoid tumors with SpringWorks Therapeutics’ Ogsiveo, now part of Merck KGaA. Evercore ISI analyst Cory Kasimov called the data a “knockout” at the time. Reuters
Friday’s price puts IMNM back around the $21.50 level where Immunome priced a $400 million public offering in December, a deal that boosted funding but increased share count. The company sold 18.625 million shares in that sale, it said.
But the next leg depends on regulators, labeling and uptake — not the hiring paperwork. Timelines can slip, and competitive pricing and reimbursement can hit the commercial math even when trial data look clean.
Next up is Immunome’s scheduled slot at the J.P. Morgan Healthcare Conference on Jan. 14 at 10:30 a.m. PST, according to the company’s events calendar. The company has not confirmed its next earnings date; MarketBeat estimates March 18 based on past reporting patterns.
